Pharmacoeconomics

Current Opinion in Gastroenterology

Volumn 12, Issue SUPPL. 1, 1996, Pages 45-49

  Deltenre, Michel ^a   Jönsson, Bengt ^b  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^b STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; OMEPRAZOLE; RANITIDINE;

COST CONTROL; DRUG COST; DUODENUM ULCER; ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; MAINTENANCE THERAPY; PATIENT CARE; PHARMACOECONOMICS; SHORT SURVEY; TREATMENT OUTCOME;

EID: 0029973213     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199601001-00011     Document Type: Short Survey

References (18)

1. Bell GD, Powell KU, Bolton GH, Richardson PDI: Clinical and pharmacoeconomic evaluation of management strategies for duodenal ulcer disease. Br J Med Econ 1993, 6:45-58.
2. Campbell LM: The role of a Helicobacter pylori eradication regimen (omeprazole plus amoxycillin) in the long-term management of ulcer-like dyspepsia in general practice. Br J Med Econ 1994, 7:147-153.
3. 2-receptor antagonists in general practice: clinical and financial consequences of eradication using omeprazole plus amoxycillin or 'triple therapy'. Br J Med Econ 1994, 7:35-41.
4. Kolts BE, Joseph B, Achem SR, Bianchi T, Monteiro C: Helicobacter pylori detection: a quality and cost analysis. Am J Gastroenterol 1993, 88:650-655.
5. Powell KU, Bell GD, Bolton GH, Burridge SM, Bowden AF, Rameh B, Hart L, Bradley P, Harrison G, Gant PW, et al.: Helicobacter pylori eradication in patients with peptic ulcer disease: clinical consequences and financial implications. Q J Med 1994, 87:283-290.
6. O'Brien B, Goeree R, Hafeez M, Hunt R: Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Arch Intern Med 1995, 155:1958-1963. The analysts provides economic evidence in support of the recent guidance that for persons with duodenal ulcer, early attempts to eradicate H. pylori are recommended.
7. Unge P, Jönsson B, Stålhammar N-O: The cost-effectiveness of Helicobacter pylori eradication versus maintenance and episodic treatment in duodenal ulcer patients In Sweden. Pharmacoeconomics 1995, 8:410-427. Using a Markov chain approach, Swedish cost data and a study period of 5 years, we concluded that H. Pylori eradication with omeprazole and appropriate antibiotics is a cost-effective alternative compared with both maintenance and episodic treatment.
8. Sonnenberg A, Townsend WF: Costs of duodenal ulcer therapy with antibiotics. Arch Intern Med 1995, 155:922-928. Compared with other options, antibiotics to eradicate H. pylori are the cheapest therapy for duodenal ulcer disease and provide the most time free of duodenal ulcer.
9. Bell GD, Powell KU, Burridge SM, Bowden AF, Atoyebi W, Bolton GH, Jones PH, Brown C: Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 1995, 9:41-46.
10. 2-receptor antagonist provides the lowest costs per symptomatic cure.
11. Jönsson B: Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease. Scand J Gastroenterol 1996, 31(suppl 215):90-95. A model analysis comparing H. pylori eradication with conventional treatment, in patients with duodenal ulcer disease, clearly shows that H. pylori eradication is a more cost-effective therapy and that treatment regimes that give higher eradication rates are cost-effective.
12. Vakil N, Fennerty MB: Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer. Am J Gastroenterol 1996, 91:239-245.
13. Treiber G: The influence of drug dosage on the Helicobacter pylori eradication: a cost-effectiveness analysis. Am J Gastroenterol 1996, 91:246-247.
14. Fendrick AM, Chernew ME, Hirth RA, Bloom BS: Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med 1995, 123:260-268. The safety and effectiveness of less expensive, less invasive diagnostic and treatment strategies strongly support the initial non-invasive care of symptomatic patients thought to have peptic ulcer disease.
15. 2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994, 343:811-816.
16. Silverstein MD, Petterson T, Nicholas JT: Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology 1996, 110:72-83. This study compares the direct medical charges in the first year after onset of dyspepsia for patients managed by initial endoscopy or empirical therapy. The conclusion is that costs and life expectancy are the same for both strategies.
17. Deltenre M, Jonas C, Van Gossum M, Buset M, Otero J, De Koster E: Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients. Eur J Gastroenterol Hepatol 1995, 7(suppl 1):S39-S44.
18. Deltenre M, Jonas C, Otero J, Cozzoli, Denis P, Burette A, De Koster E: Strategies for Helicobacter pylori eradication in 1995: a review of international and Belgian experience. J Physiol Pharmacol 1996, 47:59-69.